EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)

A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

Caicun Zhou, Yanping Hu, Ekaterine Arkania, Saadettin Kilickap, Kejing Ying, Fei Xu, Lin Wu, Xiang Wang, Maksym Viguro, Tamta Makharadze, Hongmei Sun, Feng Luo und 15 weitere

Cancer Cell · 2024-02 · 42 (2) · 198-208.e3

DOI: 10.1016/j.ccell.2023.12.004 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Cell, 2024-02. Verfasst von Caicun Zhou und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China. Electronic address: caicunzhoudr@163.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous CellHumansAntineoplastic Combined Chemotherapy ProtocolsPaclitaxelCarboplatinAntibodies, MonoclonalImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

PD-1PD-L1first-linephase 3serplulimabsquamous non-small-cell lung cancer

Substanzen

PaclitaxelCarboplatinAntibodies, MonoclonalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China. Electronic address: caicunzhoudr@163.com.
  • Department of Medical Oncology, Hubei Cancer Hospital, Wuhan 430000, China.
  • LTD Israeli-Georgian Medical Research Clinic "Helsicore", Tbilisi 0112, Georgia.
  • Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey.
  • Department of Pneumology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
  • Department of Pneumology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.

Zitieren

APA

Zhou, C., Hu, Y., Arkania, E., Kilickap, S., Ying, K., Xu, F., Wu, L., Wang, X., Viguro, M., Makharadze, T., Sun, H., Luo, F., Shi, J., Zang, A., Pan, Y., Chen, Z., Jia, Z., Kuchava, V., Lu, P., …, & ASTRUM-004 Investigators (2024). A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell, 42(2), 198-208.e3. https://doi.org/10.1016/j.ccell.2023.12.004

Vancouver

Zhou C, Hu Y, Arkania E, Kilickap S, Ying K, Xu F, et al. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell. 2024;42(2):198-208.e3. doi:10.1016/j.ccell.2023.12.004

BibTeX
@article{Zhou2024,
  author = {Zhou, Caicun and Hu, Yanping and Arkania, Ekaterine and Kilickap, Saadettin and Ying, Kejing and Xu, Fei and Wu, Lin and Wang, Xiang and Viguro, Maksym and Makharadze, Tamta and Sun, Hongmei and Luo, Feng and Shi, Jianhua and Zang, Aimin and Pan, Yueyin and Chen, Zhendong and Jia, Zhongyao and Kuchava, Vladimer and Lu, Ping and Zhang, Ling and Cheng, Ying and Kang, Wenying and Wang, Qingyu and Yu, Haoyu and Li, Jing and Zhu, Jun and ASTRUM-004 Investigators, ASTRUM-004 Investigators},
  title = {A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {2},
  pages = {198--208.e3},
  doi = {10.1016/j.ccell.2023.12.004}
}
Kostenlos starten →